Bromokriptin
Bromokriptin (INN) (Parlodel, Cikloset), je derivat ergolina. On je dopaminski agonist koji se koristi za lečenje tumora hipofize, Parkinsonove bolesti, hiperprolaktinamije, neuroleptičkog malignog sindroma, i tipa 2 dijabetesa.[6][7]
| |||
| (IUPAC) ime | |||
|---|---|---|---|
| (5′α)-2-bromo-12′-hidroksi-5′-(2-metilpropil)-3′,6′,18-triokso-2′-(propan-2-il)ergotaman | |||
| Klinički podaci | |||
| Robne marke | Parlodel | ||
| AHFS/Drugs.com | Monografija | ||
| MedlinePlus | a682079 | ||
| Identifikatori | |||
| CAS broj | 25614-03-3 | ||
| ATC kod | G02CB01 N04BC01 | ||
| PubChem[1][2] | 31101 | ||
| DrugBank | APRD00622 | ||
| ChemSpider[3] | 28858 | ||
| UNII | 3A64E3G5ZO 
| ||
| KEGG[4] | D03165
| ||
| ChEBI | CHEBI:3181
| ||
| ChEMBL[5] | CHEMBL493
| ||
| Hemijski podaci | |||
| Formula | C32H40BrN5O5 | ||
| Mol. masa | 654,595 | ||
| SMILES | eMolekuli & PubHem | ||
| |||
| Farmakokinetički podaci | |||
| Bioraspoloživost | 28% oralne doze se apsorbuje | ||
| Metabolizam | ? | ||
| Poluvreme eliminacije | 12-14 data | ||
| Izlučivanje | 85% žuč (fekalije) | ||
| Farmakoinformacioni podaci | |||
| Trudnoća | B(US) | ||
| Pravni status | ? | ||
| Način primene | oralno | ||
Farmakologija uredi
Bromokriptin je potentan agonist dopaminskog D2 receptora[8] i raznih serotoninskih receptora. On takođe inhibira oslobađanje glutamata, promenom smera glutamat GLT1 transportera.[9]
Hemija uredi
Poput svih ergopeptida, bromokriptin je ciklol. Dve peptidne grupe njegovog tripeptidnog strukturnog segmenta su umrežene, čime je formirana >N-C(OH)< veza između dva prstena sa amidnom funkcionalnom grupom.
Bromokriptin, 2-bromoergokriptin, je semisintetički derivat prirodnog ergot alkaloida, ergokriptina (derivata liserginske kiseline), koji se sintetiše brominacijom ergokriptina koristeći N-bromosukcinimid.[10][11]
Izvori uredi
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.
- ↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
- ↑ Pdr Staff (2009). PDR: Physicians Desk Reference 2010 (Physicians' Desk Reference (Pdr)). Rozelle, N.S.W: Thomson Reuters. ISBN 1-56363-748-0.
- ↑ De Leeuw Van Weenen J. E., Parlevliet E. T., Maechler P., Havekes L. M., Romijn J. A., Ouwens D. M., Pijl H., Guigas B. (2010). „The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the α2-adrenergic receptors in beta cells”. Biochemical Pharmacology 79 (12): 1827. DOI:10.1016/j.bcp.2010.01.029. PMID 20138024.
- ↑ „ScienceDirect - European Journal of Pharmacology : Bromocriptine, an ergot alkaloid, inhibits excitatory amino acid release mediated by glutamate transporter reversal”. Pristupljeno 31. 8. 2010.
- ↑ E. Fluckiger, A. Hoffmann, U.S. Patent 3.752.814 (1973).
- ↑ A. Hofman, E. Flueckiger, DE 1926045 (1969).